Kalaris Therapeutics — Third Quarter 2026 Earnings Summary

Kalaris Therapeutics reported a net loss of $11.0 million for the third quarter ended September 30, 2026, with cash, cash equivalents, and marketable securities totaling $82.9 million. The company expects its current cash reserves to fund operations into 2028, extending beyond the anticipated readout of Phase 1b/2 data for its drug candidate TH103 in neovascular age-related macular degeneration. Preliminary data from the ongoing Phase 1b/2 study is now projected for the second half of 2027 following a supply interruption that delayed the availability of a new drug batch until the second quarter of 2027. Despite the delay, Kalaris successfully completed the technology transfer of TH103 to a commercial-scale manufacturer, with test batches meeting target specifications for future Phase 3 development.